Cardiac MRI accurate for suspected cardiac tumor

Cardiac MRI accurate for suspected cardiac tumor

Cardiac MRI demonstrated high diagnostic accuracy in patients with suspected cardiac tumors and may serve as a good independent predictor of long-term survival, researchers reported.
Expert consider CMR as a key diagnostic tool in the evaluation of patients with suspected cardiac tumors
The present study is the largest imaging study to date for the diagnosis of cardiac tumor and confirms the high accuracy of CMR previously reported in smaller cohorts in whom cardiac tumors were known to be present

Read the full study:
https://www.healio.com/news/cardiology/20211008/cardiac-mri-accurate-for-suspected-cardiac-tumor-predictive-of-longterm-outcomes

Radiologists prefer a subspecialized reporting system

Back in January 2018, a Swiss health system retooled its workflow to create a centralized reporting network. The restructuring also created organ-based radiology teams and most radiologists were relocated from satellite facilities to the main hospital.
The thinking was that consolidated reporting would make life easier for imaging team members as well as referring physicians. After sending out 400 questionnaires to assess the project, researchers found that more than 95% of radiologists preferred the update.

Read the entire study here.

4D flow imaging as a predictive tool for aortic disease

4D flow magnetic resonance imaging (MRI) has the potential to identify patients with a higher risk of severe complications from aortic degeneration Northwestern Medicine study published. The study employed a new 4D flow MRI heatmap concept to detect abnormal aortic wall shear stress, a known stimulus for arterial wall dysfunction.

This publication showcases data to validate 4D flow imaging as a clinical predictive tool for bicuspid aortopathy. Clinicians can use this imaging tool and biomarker to help be more precise about prophylactic aortic resection.

Read more: https://www.news-medical.net/news/20210913/Study-suggests-4D-flow-imaging-as-a-clinical-predictive-tool-for-aortic-disease.aspx

Experts give top tips on how to succeed in breast imaging

What personal qualities and attributes do you need to achieve success in breast imaging? How should you approach artificial intelligence (AI)? How can you conduct better research projects? And what can be said about the future?

Committee members of the Young Club of the European Society of Breast Imaging (EUSOBI) put these questions to 11 senior officials and members of the organization. The experts were asked to give their answers in the form of three top tips.

Find out what their tips are: https://www.auntminnieeurope.com/index.aspx?sec=ser&sub=def&pag=dis&ItemID=620563

6 issues radiology must address after COVID-19

A panel at the Association of University Radiologists(AUR) identified six themes that the radiology industry must address post COVID-19.

1. Individual and organizational resilience.
2. Patient care disparities and inequities.
3. Telehealth and remote work functionality.
4. Prioritizing innovations and technological advances.
5. Determining societal responsibility of radiology practices and industry.
6. Need for business models that support partnerships between academia and industry.

New PET imaging agent alters prostate cancer plan for more than 40% of patients

A recently developed PET imaging agent is earning praise following positive clinical trial results in men with high-risk prostate cancer.

North Billerica, Massachusetts-based Lantheus presented early findings from a study at the recent American Urological Association virtual meeting. The PSMA-targeted agent—piflufolastat F-18—detected disease that had spread outside the prostate in nearly one-third of men.

Additionally, an independent, retrospective review showed the imaging agent led to possible changes in care management strategy for 43.6% of patients, including decisions regarding surgery or radiation therapy.

Read more: https://www.healthimaging.com/topics/molecular/pet-agent-alters-prostate-cancer-plan

Newly identified mechanism can accelerate the development of STING-activating drugs using imaging

A new study from scientists at the UCLA Jonsson Comprehensive Cancer Center found that emerging drugs that activate the protein STING, substantially alter the activity of metabolic pathways responsible for generating the nucleotide building blocks for DNA. 

Researchers found that alterations occur in cancer cells and can be visualized using FLT positron emission tomography (PET) imaging, marking the first time the effects of these drugs have been traced using a noninvasive imaging technique.

Understanding how STING agonists impact metabolic processes can help accelerate the clinical development of STING activating drugs in various therapeutic settings and guide the design of novel biomarkers and combination therapies.

Read more: https://www.news-medical.net/news/20210907/Newly-identified-mechanism-can-accelerate-the-development-of-STING-activating-drugs-using-imaging.aspx